Focused On-demand Library for Caprin-2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6IMN6

UPID:

CAPR2_HUMAN

Alternative names:

C1q domain-containing protein 1; Cytoplasmic activation/proliferation-associated protein 2; Gastric cancer multidrug resistance-associated protein; Protein EEG-1; RNA granule protein 140

Alternative UPACC:

Q6IMN6; E4NKG2; Q149P6; Q149P7; Q6IMN5; Q7Z371; Q8TE70; Q8TE71; Q96RN6; Q9H667; Q9HAL4

Background:

Caprin-2, also known as C1q domain-containing protein 1 and several other names, plays a crucial role in cellular processes. It promotes phosphorylation of LRP6, enhancing the canonical Wnt signaling pathway, vital for cell proliferation and differentiation. Additionally, it's involved in mRNA transport and translation, affecting protein expression in synaptic plasticity, and plays a role in erythroblast differentiation and potentially in apoptosis.

Therapeutic significance:

Understanding the role of Caprin-2 could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways and cellular processes suggests its potential as a target in diseases where these pathways are dysregulated.